New oral anticoagulants—what the cardiothoracic surgeon needs to know Tsuyoshi Kaneko, MD, Maroun Yammine, MD, Sary F. Aranki, MD The Journal of Thoracic and Cardiovascular Surgery Volume 148, Issue 5, Pages 1794-1801.e1 (November 2014) DOI: 10.1016/j.jtcvs.2014.05.060 Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions
Figure 1 Perioperative management of a patient undergoing major cardiothoracic surgery who is taking (A) warfarin or (B) new oral anticoagulants (NOACs). UFH, Unfractionated heparin; LMWH, low-molecular-weight heparin; INR, international normalized ratio; aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; DVT, deep venous thrombosis; CrCl, creatinine clearance; TT, thrombin time. *Risk stratification according to American College of Chest Physician 2012 guidelines.27 The Journal of Thoracic and Cardiovascular Surgery 2014 148, 1794-1801.e1DOI: (10.1016/j.jtcvs.2014.05.060) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions